These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 24289528)

  • 41. Immediate postabortion initiation of levonorgestrel implants reduces the incidence of births and abortions at 2 years and beyond.
    Rose SB; Garrett SM; Stanley J
    Contraception; 2015 Jul; 92(1):17-25. PubMed ID: 25818594
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sexual function and quality of life of women adopting the levonorgestrel-releasing intrauterine system (LNG-IUS 13.5 mg) after abortion for unintended pregnancy.
    Caruso S; Cianci S; Vitale SG; Fava V; Cutello S; Cianci A
    Eur J Contracept Reprod Health Care; 2018 Feb; 23(1):24-31. PubMed ID: 29436865
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prolonged use of the etonogestrel implant and levonorgestrel intrauterine device: 2 years beyond Food and Drug Administration-approved duration.
    McNicholas C; Swor E; Wan L; Peipert JF
    Am J Obstet Gynecol; 2017 Jun; 216(6):586.e1-586.e6. PubMed ID: 28147241
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Assessment of biomarkers in women with endometriosis-associated pain using the ENG contraceptive implant or the 52 mg LNG-IUS: a non-inferiority randomised clinical trial.
    Margatho D; Mota Carvalho N; Eloy L; Bahamondes L
    Eur J Contracept Reprod Health Care; 2018 Oct; 23(5):344-350. PubMed ID: 30372645
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Reasons for Brazilian women to switch from different contraceptives to long-acting reversible contraceptives.
    Ferreira JM; Nunes FR; Modesto W; Gonçalves MP; Bahamondes L
    Contraception; 2014 Jan; 89(1):17-21. PubMed ID: 24156884
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Randomised comparative trial of thermal balloon ablation and levonorgestrel intrauterine system in patients with idiopathic menorrhagia.
    Shaw RW; Symonds IM; Tamizian O; Chaplain J; Mukhopadhyay S
    Aust N Z J Obstet Gynaecol; 2007 Aug; 47(4):335-40. PubMed ID: 17627692
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The levonorgestrel-releasing intrauterine system for endometrial protection during estrogen replacement therapy: a clinical review.
    Depypere H; Inki P
    Climacteric; 2015; 18(4):470-82. PubMed ID: 25553775
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A Comparison of Breastfeeding Exclusivity and Duration Rates Between Immediate Postpartum Levonorgestrel Versus Etonogestrel Implant Users: A Prospective Cohort Study.
    Krashin JW; Lemani C; Nkambule J; Talama G; Chinula L; Flax VL; Stuebe AM; Tang JH
    Breastfeed Med; 2019; 14(1):69-76. PubMed ID: 30508390
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The use of different doses levonorgestrel-releasing intrauterine system (LNG-IUS): real-world data from a multicenter Italian study.
    Bastianelli C; Farris M; Rosato E; Varliero F; Del Savio MC; Facchinetti F; Grandi G
    Eur J Contracept Reprod Health Care; 2022 Feb; 27(1):16-22. PubMed ID: 34528867
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Resources and procedures in the treatment of heavy menstrual bleeding with the levonorgestrel-releasing intrauterine system (LNG-IUS) or hysterectomy in Brazil.
    Bahamondes MV; de Lima Y; Teich V; Bahamondes L; Monteiro I
    Contraception; 2012 Sep; 86(3):244-50. PubMed ID: 22459236
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sixty thousand woman-years of experience on the levonorgestrel intrauterine system: an epidemiological survey in Finland.
    Backman T; Huhtala S; Tuominen J; Luoto R; Erkkola R; Blom T; Rauramo I; Koskenvuo M
    Eur J Contracept Reprod Health Care; 2001 Jan; 6 Suppl 1():23-6. PubMed ID: 11336430
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Uptake and continuation rates of the intrauterine system in a university student general practice population in the UK.
    Armitage CM; Mitchell C; Wigan C; Smith DA
    J Fam Plann Reprod Health Care; 2013 Jul; 39(3):186-9. PubMed ID: 23243152
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ease of insertion, contraceptive efficacy and safety of new T-shaped levonorgestrel-releasing intrauterine systems.
    Wildemeersch D; Janssens D; Vrijens M; Weyers S
    Contraception; 2005 Jun; 71(6):465-9. PubMed ID: 15914138
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Timing of postpartum etonogestrel-releasing implant insertion and bleeding patterns, weight change, 12-month continuation and satisfaction rates: a randomized controlled trial.
    Vieira CS; de Nadai MN; de Melo Pereira do Carmo LS; Braga GC; Infante BF; Stifani BM; Ferriani RA; Quintana SM
    Contraception; 2019 Oct; 100(4):258-263. PubMed ID: 31145885
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Malposition and expulsion of the levonorgestrel intrauterine system among women with inherited bleeding disorders.
    Rimmer E; Jamieson MA; James P
    Haemophilia; 2013 Nov; 19(6):933-8. PubMed ID: 23711358
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Use of long-acting reversible contraceptives in the UK from 2004 to 2010: analysis using The Health Improvement Network Database.
    Cea Soriano L; Wallander MA; Andersson S; Filonenko A; García Rodríguez LA
    Eur J Contracept Reprod Health Care; 2014 Dec; 19(6):439-47. PubMed ID: 25139412
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Study of long-acting reversible contraceptive use in a UK primary care database: validation of methodology.
    Cea Soriano L; Wallander MA; Andersson SW; Requena G; García-Rodríguez LA
    Eur J Contracept Reprod Health Care; 2014 Feb; 19(1):22-8. PubMed ID: 24229345
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immediate versus delayed insertion of an etonogestrel releasing implant at medical abortion-a randomized controlled equivalence trial.
    Hognert H; Kopp Kallner H; Cameron S; Nyrelli C; Jawad I; Heller R; Aronsson A; Lindh I; Benson L; Gemzell-Danielsson K
    Hum Reprod; 2016 Nov; 31(11):2484-2490. PubMed ID: 27664217
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effectiveness and continuation rates of the etonogestrel-subdermal contraceptive implant versus short-acting contraceptive methods offered at no cost in Campinas, Brazil.
    Laporte M; Marcelino AC; da Cunha Pereira P; Espejo-Arce X; Juliato CT; Bahamondes L
    Int J Gynaecol Obstet; 2024 Jul; 166(1):305-311. PubMed ID: 38328989
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Twelve-month discontinuation of etonogestrel implant in an outpatient pediatric setting.
    Berlan E; Mizraji K; Bonny AE
    Contraception; 2016 Jul; 94(1):81-6. PubMed ID: 26948183
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.